Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congress 2024 Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congre

Atypical Hemolytic Uremic Syndrome (aHUS) Market and Forecast Through 2032 Reveals Growth and Treatment Shifts Dublin, April 08, 2024 (GLOBE NEWSWIRE) -- The "Atypical Hemolytic Uremic Syndrome (aHUS) - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ...

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review 2024 Dublin, Feb. 23, 2024 (GLOBE NEWSWIRE) -- The "Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides...